Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (267)	7/28/1998 6:35:00 PM
From: Rigorous	Read Replies (1) \| Respond to of 399

E r i c B . G o r d o n joined ArQule as President and Chief Executive Officer in January, 1996. He is a seasoned industry executive who served stateside and in Europe (1987-1995) with the U.S. pharmaceutical firm Pasteur Merieux Connaught-US, the world's largest developer of vaccines. Mr. Gordon held the positions of Corporate Vice President, Treasurer, CFO and Chief Executive Officer of Virogenetics Corporation, a joint venture company (1993-1995). Prior to 1987, he was Vice President of Sterling Drug, Inc. OTC Products Group. Mr. Gordon earned an AMP at the Wharton School of Business, and a B.S. in Accounting and Finance at Syracuse University. from: arqule.com Is there a bio available for the Versicor Gordon?